Amphastar Pharmaceuticals, Inc. (AMPH)
Healthcare
- Fundamental
- 4
- Sentiment
- 3
- Technical
- 4
Momentum breakout: AMPH is in a strong uptrend (price above SMA20/50/200, ADX 40.79) consolidating just under 24.39 resistance. Buy-stop entry at 24.40 above the swing high targets a continuation toward 25.86 / 26.96, with a structural protective stop at 23.34 below the 2-session consolidation floor; R/R 1.38.
Company overview
Amphastar Pharmaceuticals, Inc., based in Rancho Cucamonga, California, develops, manufactures, and markets generic and proprietary pharmaceuticals, including injectables, inhalants, and intranasal formulations. The company's operations are divided into Finished Pharmaceutical Products and Active Pharmaceutical Ingredients, serving markets in the U.S., China, and France. Its product range includes treatments for asthma, deep vein thrombosis, opioid overdose, and other medical conditions.
Fundamental
goodAmphastar is profitable and cash-generative, with inexpensive valuation metrics and strong liquidity, despite recent margin declines and regulatory concerns.
Profitable, cash-generative specialty/generic drug manufacturer trading at relatively low multiples (P/E ~12; EV/EBITDA ~8) with strong liquidity. The key concerns are the step-down in earnings/margins since 2024 and the FDA warning letter/remediation disclosed in the latest quarterly filing; Street price targets sit roughly around the current quote, suggesting skepticism despite very high DCF-implied values.
Sentiment
fairMedia sentiment has improved post-earnings, but FDA compliance issues remain a significant overhang.
Near-term narrative is anchored by the Q2 results release (2026-08-06, announced), which has been framed positively in recent coverage but with limited article volume. Versus the prior 30–90d window that leaned slightly negative on FDA warning-letter and analyst-target-cut headlines, media tone has improved; no regulator-confirmed investigations surfaced, though manufacturing-compliance scrutiny remains an overhang.
Technical
goodThe stock is in a confirmed uptrend, consolidating just below resistance, with bullish momentum indicators.
AMPH is in a strong, ADX-confirmed uptrend (ADX 40.79, rising, with price above the SMA20 22.77, SMA50 21.01 and SMA200 22.42, and above both EMAs). Momentum is bullish: RSI 68.23, Williams %R -15.33, MACD line 0.82 above signal 0.79 with a positive, if slightly narrowing, histogram (0.03). The stock has spent three sessions consolidating just under 24.39 resistance after two probes (24.28 on Sep 14, 24.39 on Sep 16), forming a tight base above 23.49-23.56. Volume confirms demand: avgDollarVolume20 is ~$9.14M against a $5M floor, and up-days carry more volume than down-days. A buy-stop above 24.39 confirms the breakout; the structural stop sits below the 2-session consolidation floor (23.34 = swingLow 23.49 - 0.15 buffer), a level whose break would invalidate the setup. Risk 1.06 = 1.45xATR, clearing the 0.5xATR floor at 3.05% ATR. One soft signal: momentum deceleration (narrowing histogram) and RSI approaching overbought; hence technicalScore 4, not 5.
You’re looking at 2026-09-17 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.